Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Multiple myeloma combo trial halted after just 4 patients

NCT ID NCT06163898

First seen May 06, 2026 · Last updated May 23, 2026 · Updated 3 times

Summary

This early-stage study aimed to find the best dose and check the safety of combining alnuctamab and mezigdomide for people with multiple myeloma that had come back or stopped responding to treatment. Only 4 participants were enrolled before the study was stopped early. The main goals were to track side effects and see if the combination helped control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Local Institution - 0018

    New York, New York, 10065, United States

  • Local Institution - 0020

    Jerusalem, 9112001, Israel

  • Local Institution - 0021

    Petah Tikva, Central District, 4910021, Israel

  • Local Institution - 0030

    Ramat Gan, Central District, 5262100, Israel

  • Local Institution - 0033

    Birmingham, Alabama, 35294, United States

  • Local Institution - 0035

    New Haven, Connecticut, 06511, United States

Conditions

Explore the condition pages connected to this study.